Bio.com Life Sciences News Update
August 7, 2002
Produced by Bio Online(r)
Portal to the Life Sciences(tm)
www.bio.com | www.bioprotocol.com
===========================================================================
CONTENTS:
===========================================================================
1. Science News: "New Perspective on Evolution"
2. InFocus: "Cellular Signaling" - Listen to what the experts have to say
3. Career Center: The "Next Generation" Career Center is here
4. Jobs of the Week: "Senior Research Associate" and others
5. Market Research: "Ion Channel Assays in the Drug Discovery Process"
6. Featured Software: "MolSuite 2000" and others
========================================================================
1. SCIENCE NEWS
===========================================================================
-Structure of Key Receptor Unlocked
http://www.bio.com/jump.jhtml?id=100001
After two years of stubborn persistence, scientists at Johns Hopkins have
determined the 3-D structure of part of a protein called HER3, which should
speed efforts to interfere with abnormal growth and cancer.
-New Method for DNA Detection
http://www.bio.com/jump.jhtml?id=100002
Researchers at the University of California at Santa Barbara report a new
method for detecting DNA, which could transform medical diagnostics. They
combine the use of a light-emitting polymer with peptide nucleic acid (PNA)
probes to make a test so sensitive that costly DNA amplification can be
reduced and perhaps eliminated.
-Physical Map of Mouse Genome Available
http://www.bio.com/jump.jhtml?id=100003
A physical map of the genetic makeup of a mouse--the mouse genome--is 98
percent complete and is being released online by the journal Nature.
Researchers at the Genome Sequencing Center at Washington University School
of Medicine in St. Louis played a major role in the international effort, as
they did in the sequencing and mapping of the human genome.
-Gene Therapy Boosts Cancer Chemotherapy
http://www.bio.com/jump.jhtml?id=100004
Researchers at the University of Chicago have found a way to combine cancer
chemotherapy with gene therapy designed to disrupt the growth of blood
vessels to a tumor. The combination, tested in mice, is far more effective
than standard chemotherapy and has no additional side effects. This new
approach evolved out of a similar system, now entering phase-2 human trials,
that combines gene therapy with radiation therapy.
-New Perspective on Evolution
http://www.bio.com/jump.jhtml?id=100005
Why, biologists first asked 60 years ago, do members of the same species
have such similar traits, or phenotypes, despite the fact that they have
such diverse genes, or genotypes? Senior research scientist Aviv Bergman of
Stanford's Center for Computational Genetics and Biological Modeling (CCGBM)
and postdoctoral scholar Mark Siegal of the Department of Biological
Sciences provide a surprisingly simple answer.
-Mice Provide Insight Into Bone Metabolism
http://www.bio.com/jump.jhtml?id=100006
Mice lacking a protein called SHIP have twice as many cells that breakdown
bone as normal mice, according to a study led by Washington University
School of Medicine in St. Louis. Consequently, the mice lose a significant
amount of bone density and thickness. These results not only provide insight
into diseases of bone metabolism such as osteoporosis, but the mouse strain
used in the study also may be the first animal model of a rare genetic
disease called juvenile Paget's disease (JPD).
-FEATURE: The Practical Dream of Cancer Therapies and Vaccines
http://www.bio.com/jump.jhtml?id=100007
To dream of helping the masses who are every year treated for cancer or of
saving over 500,000 Americans who succumb every year to cancer is
perhaps to slip into foolhardy fantasies. Immunology Professor Ralph Reisfeld
freely admits to being a dreamer, although he is also enough of a realist to
avoid using the word cure. He is working on immunotherapies and DNA vaccines
as possible ways to prevent cancer.
To view Industry news, visit:
http://www.bio.com/jump.jhtml?id=100008
To view Research news, visit:
http://www.bio.com/jump.jhtml?id=100009
===========================================================================
2. INFOCUS WEBCAST
===========================================================================
1) "Cellular Signaling"
Broadcast Thursday, August 1, 2002
*Click here to listen to the audio recording:
http://www.bio.com/jump.jhtml?id=100010
*Click here to enter a drawing for a giveaway from our sponsors:
http://www.bio.com/jump.jhtml?id=100011
*To view all past InFocus Webcast recordings and transcripts, go to:
http://www.bio.com/jump.jhtml?id=100012
===========================================================================
3. CAREER CENTER
===========================================================================
Tired of searching for jobs day after day?
Let Bio.com do the job search for you!
Bio.com works on behalf of selected employers in the life sciences industry to
look for top candidates like you. It's a personalized service that ensures:
-You will ONLY be contacted for positions that FIT your background.
-Strict Confidentiality: Unlike other sites that allow recruiters full access to
their resume database, Bio.com will maintain your anonymity until you choose to
be contacted by any given employer.
As a Bio.com Member, you will also enjoy Bio.com's new Career Center Tool
that allows you to:
-Gain access to thousands of life sciences job opportunities
(http://www.bio.com/jump.jhtml?id=100013)
-Receive Job Agent alerts for jobs that match your criteria
-Apply for jobs with a one click application process
-Maintain/store your resume confidentially
-Receive monthly e-newsletter with "Featured Jobs" and "Featured Employers"
These services are FREE for you to use. So, what are you waiting for?
Sign up for your Bio.com Membership and start your job search today!
http://www.bio.com/jump.jhtml?id=100014
===========================================================================
4. JOBS OF THE WEEK
===========================================================================
Look at what's new in the Bio.com Career Center this week:
1. Essential Therapeutics: Pharmaceutical Scientist
http://www.bio.com/jump.jhtml?id=100015
2. Ligand Pharmaceuticals: Senior Research Associate
http://www.bio.com/jump.jhtml?id=100016
3. Acumen Sciences: Director, Biological Sciences Research
http://www.bio.com/jump.jhtml?id=100017
4. Baystate Health System: Genetics Director
http://www.bio.com/jump.jhtml?id=100030
5. Ricerca Biosciences: Business Development Director/Manager
(MS or PH.D)
http://www.bio.com/jump.jhtml?id=100027
6. Setren Smallberg & Associates: Process Development Scientist
http://www.bio.com/jump.jhtml?id=100028
7. DHR International: VP of Sales and Marketing
http://www.bio.com/jump.jhtml?id=100029
Register today and start using our new features:
http://www.bio.com/jump.jhtml?id=100018
Click here to browse all jobs from Bio.com's Career Center:
http://www.bio.com/jump.jhtml?id=100019
===========================================================================
5. MARKET RESEARCH
===========================================================================
Bio.com offers the most comprehensive collection of market research.
-Ion Channel Assays in the Drug Discovery Process
http://www.bio.com/jump.jhtml?id=100020
The pharmaceutical industry is faced with two central
confrontations-increased throughput of new chemical entities (NCEs), and
greater originality in terms of addressable biological targets. Ion channels
are significant pharmaceutical targets with ion channel-targeted drugs
generating over 6 billion dollars in sales per annum. However, the
development of technology for ion-channel screening has faced significant
hurdles. This report Ion Channel Assays in the Drug Discovery Process is
produced to compile and assess available and future possibilities in ion
channel assays. It views a competitive landscape of companies in this field
and guides the user in technologies that suit different segments of the drug
discovery process.
-Neurological Trauma Therapeutics: Markets & Developments
http://www.bio.com/jump.jhtml?id=100021
CNS disorder therapeutics are second only to cardiovascular therapeutics in
average sales per compound. New research approaches--including stem cell
research--hold the promise of the first effective treatments for some
disorders, as well as blockbuster compounds for their developers. But
several challenges--not all of them scientific--stand in the way of
breakthrough treatments. Neurological Trauma Therapeutics: Markets &
Developments examines the conditions in this arena, answering the most
urgent and pressing questions affecting business in this area.
-Breaking the Bottlenecks: Applying Genomics Throughout Drug Discovery and
Development
http://www.bio.com/jump.jhtml?id=100022
Although approaches for analyzing and exploiting vast amounts of genomic
data promise to improve and accelerate the drug discovery development
process, major bottlenecks remain at every step in this process, from target
identification and validation, to lead discovery and optimization, to
preclinical testing, to clinical development. This report examines where the
bottlenecks are, what companies and technologies are addressing these
inefficiencies, and what future breakthroughs are needed. The activities of
more than 80 companies are reviewed, and insights from more than 20 industry
experts are included.
Click here to browse through our publications catalogue:
http://www.bio.com/jump.jhtml?id=100023
===========================================================================
6. FEATURED SOFTWARE
===========================================================================
Bio.com offers a very comprehensive selection of Life Science related
software. Check out these latest additions:
-SpecManPlus
http://www.bio.com/jump.jhtml?id=100024
This software provides an interactive graphical analysis tool for scientists
working with a variety of spectroscopic data. It imports a variety of
formats (Bruker, Varian, JEOL, NMRPipe, NUTS, Felix, JCAMP, Galactic, Triad,
NMR-Compass, etc.) of 1D, 2D, 3D and nD processed spectrum files for
concurrent display and analysis in multiple views. SpecManPlus enables the
user to access 1D and 2D NMR data processing programs from within
SpecManPlus. This software extracts chemical shifts and other spectral
parameters by using sophisticated peak picking procedures including
grid-intelligence-based peak picking. It also provides tools for viewing 2D
planes from 3D or nD spectra and enables tying and concurrent zooming of 2D
and 3D spectra.
-Cyrillic 3
http://www.bio.com/jump.jhtml?id=100025
Cyrillic 3 Standard Version is a user-friendly interface to your pedigree
database. This software provides pedigree drawing with fully integrated
risk analysis and support for industry standard databases (MS Access and
Corel Paradox). You draw pedigrees and edit "live" data together on-screen,
so pedigree drawing is virtually effortless! Designed for genetic counselors
and others who work with patients. If you use genetic marker data you'll
need Cyrillic 2.1.
-MolSuite 2000
http://www.bio.com/jump.jhtml?id=100026
MolSuite 2000 gives you molecular modeling with great graphics, physical
property calculations, statistical analysis, and database development and
management all in one complete package. Model building is easy in ChemSite
Pro which provides fast minimization and displaying of any molecule, even
crystals, in a 3D environment. MolSuite 2000 is a desktop chemist's
affordable integrated suite. MolSuite 2000 Includes: ChemSite Pro/Molecular
Modeling and Analysis Pro/MolSuite DB.
Click here to browse through our software catalogue:
http://www.bio.com/store/store_software.jhtml
===========================================================================
This message is sent to <qsar_society%accelrys.com> per your request
To unsubscribe, simply hit Reply from this email account <qsar_society%%accelrys.com>
and put the word 'unsubscribe' in the subject field.
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
Copyright (c) 2002 Bio Online, Inc. All rights reserved.
Received on 2002-08-07 - 05:30 GMT
This archive was generated by hypermail 2.2.0 : 2005-11-24 - 10:21 GMT